A Phase 4 interventional study of Fingolimod 0.5 mg in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 12th largest by enrollment, is the only one that started in 2015, is one of 14 in phase 4, and was the 16th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 126 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 142 across the 19 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis: 1 open now, 4 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one is the 17th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2015, is one of 15 in phase 4, and was the 22nd registered.
Novartis’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Among Novartis’s 34 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses.
Cytokines are a broad and loose category of small proteins that are important in cell signaling.
The second purpose of the study was to test the cytokine/chemokine changes measured in the 3rd and 6th months on the efficacy parameters.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fingolimod 0.5 mg
Healthy volunteers with no intervention or drug administered.
66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
Baseline Serum Cytokine and Chemokine Levels of Healthy Controls and RRMS Patients - ELISA
Blood samples were taken at baseline and measurements were performed before treatment of fingolimod.
Time frame: Baseline
Baseline Flow Cytometry Analyses for Blood Cytokines and Chemokines in Healthy Controls and RRMS Patients
baseline peripheral blood flow cytometric analysis in study participants
Time frame: Baseline
Percent Blood Cytokines and Chemokines Via Flow Cytometry Analyses of Healthy Controls and RRMS Patients at Baseline
Baseline peripheral blood flow cytometric analyses in study participants evaluated by flow cytometry analysis.
Time frame: Baseline
Serum Cytokine and Chemokine Levels inRRMS Patients Between Visits
Change of serum cytokine and chemokine levels measured by ELISA in RRMS patients treated with fingolimod between visits
Time frame: Baseline, month 3, month 6
Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients
Peripheral blood chemokine cytokine levels measured by flow cytometry during fingolimod treatment in healthy controls at baseline and in RRMS patients between visits
Time frame: Baseline, Month 3, Month 6
Absolute Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients
Peripheral blood chemokine cytokine levels measured by flow cytometry at baseline and between visits during fingolimod treatment. Absolute counts of the cells were calculated according to the absolute lymphocyte counts and the percentages of cells. This allowed for a clear determination of cell counts and thus increased the reliability of the results.
Time frame: Baseline, Month 3, Month 6
Percent of Peripheral Blood Cytokine and Chemokine Measurements in Healthy Controls and RRMS Patients
Peripheral blood chemokine cytokine levels measured by flow cytometry in healthy controls at baseline and in RRMS patients between visits during fingolimod treatment
Time frame: Baseline, Month 3, Month 6
| Milestone | FTY720 | Healthy Volunteers |
|---|---|---|
| Started | 66 | 60 |
| Completed | 54 | 60 |
| Not completed | 12 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 3 | 0 |
| Withdrew: Withdrawal by subject | 5 | 0 |
| Withdrew: Adverse event | 3 | 0 |
Blood samples were taken at baseline and measurements were performed before treatment of fingolimod.
| pg/ml | Healthy Controls | FTY720 |
|---|---|---|
| CCL5 (RANTES) | 212.26 ± 22.48 | 404.31 ± 55.189 |
| IL-17A | 1.15 ± 0.03 | 1.06 ± 0.029 |
| CXCL13 | 110.8 ± 22.3 | 139.68 ± 46.631 |
| IL6 | 0.88 ± 0.324 | 66.53 ± 65.411 |
| IL8 | 3.25 ± 0.47 | 3.57 ± 0.553 |
| IL13 | 0.49 ± 0.331 | 0.3 ± 0.15 |
| IL23 | 1.29 ± 0.552 | 3.04 ± 0.924 |
| VLA4 | 1.17 ± 0.396 | 0.58 ± 0.201 |
| CXCL10=IP-10 (CXCR3 ligand) | 16.09 ± 1.76 | 18.18 ± 2.405 |
| CCL2=MCP-1 | 52.88 ± 4.281 | 62.89 ± 8.42 |
| IL4 | 2.02 ± 0.077 | 2.36 ± 0.149 |
| TNF alpha | 1.1 ± 0.195 | 1.06 ± 0.1 |
| IL22 | 22.36 ± 0.581 | 22.41 ± 0.547 |
baseline peripheral blood flow cytometric analysis in study participants
| absolute cell count | Healthy Controls | FTY720 |
|---|---|---|
| CD3 abs | 2048.14 ± 263.209 | 1610.94 ± 126.071 |
| CD19 abs | 311.63 ± 57.592 | 327.63 ± 44.421 |
| NK abs | 281.33 ± 39.106 | 623.57 ± 394.837 |
| NKT abs | 135.86 ± 16.627 | 104.36 ± 15.080 |
| Hi CD16CD56 abs | 26.64 ± 4.399 | 20.44 ± 3.506 |
| CD4CD25 (CD3 gate) | 26.08 ± 3.159 | 27.08 ± 1.251 |
| Hi CD4CD25 (CD3 gate) | 2.83 ± 0.383 | 3.33 ± 0.253 |
Change of serum cytokine and chemokine levels measured by ELISA in RRMS patients treated with fingolimod between visits
| pg/ml | Visit 1 | Visit 2 | Visit 3 |
|---|---|---|---|
| CXCL13=BLC | 139.68 ± 46.631 | 105.42 ± 20.61 | 105.86 ± 22.053 |
| IL6 | 66.53 ± 65.411 | 49.98 ± 49.263 | 149.62 ± 144.622 |
| IL8 | 3.57 ± 0.553 | 3.84 ± 0.482 | 4.29 ± 0.541 |
| IL13 | 0.3 ± 0.15 | 0.35 ± 0.208 | 0.48 ± 0.289 |
| CCL5= RANTES | 404.31 ± 55.189 | 384.12 ± 52.649 | 480.34 ± 63.874 |
| IL23 | 3.04 ± 0.924 | 2.01 ± 0.629 | 2.15 ± 0.699 |
| VLA4 | 0.58 ± 0.201 | 0.76 ± 0.356 | 0.82 ± 0.36 |
| CXCL10=IP-10 (CXCR3 ligand) | 18.18 ± 2.405 | 18.46 ± 2.356 | 20.54 ± 3.008 |
| CCL2=MCP-1 | 62.89 ± 8.42 | 74.38 ± 10.011 | 92.73 ± 13.626 |
| IL4 | 2.36 ± 0.149 | 1.94 ± 0.099 | 2.12 ± 0.145 |
| IL17A | 1.06 ± 0.029 | 1.09 ± 0.04 | 1.04 ± 0.033 |
| TNF | 1.06 ± 0.1 | 1.26 ± 0.196 | 1.12 ± 0.139 |
| IL22 | 22.41 ± 0.69 | 22.45 ± 0.843 | 22.99 ± 0.739 |
Peripheral blood chemokine cytokine levels measured by flow cytometry during fingolimod treatment in healthy controls at baseline and in RRMS patients between visits
| pg/ml | Healthy Controls | Visit 1 | Visit 2 | Visit 3 |
|---|---|---|---|---|
| CD3 abs | 2048.14 ± 263.209 | 1610.94 ± 126.071 | 339.74 ± 43.44 | 314.75 ± 30.15 |
| CD19 abs | 311.63 ± 57.592 | 327.63 ± 44.421 | 32.9 ± 5.347 | 26.56 ± 2.879 |
| NK abs | 281.33 ± 39.106 | 623.57 ± 394.837 | 203.66 ± 30.487 | 181.97 ± 20.715 |
| NKT abs | 135.86 ± 16.627 | 104.36 ± 15.08 | 88.45 ± 12.725 | 88.98 ± 11.046 |
| Hi CD16CD56 abs | 26.64 ± 4.399 | 20.44 ± 3.506 | 29.35 ± 8.73 | 30.04 ± 6.59 |
| CD4CD25 (CD3 gate) | 26.08 ± 3.159 | 27.03 ± 1.251 | 9.24 ± 1.407 | 9.22 ± 1.399 |
| Hi CD4CD25 (CD3 gate) | 2.83 ± 0.383 | 3.33 ± 0.253 | 2.03 ± 0.302 | 1.77 ± 0.267 |
Baseline peripheral blood flow cytometric analyses in study participants evaluated by flow cytometry analysis.
| Percent of cells | Healthy Controls | FTY720 |
|---|---|---|
| CD3 % | 76.52 ± 1.494 | 71.92 ± 1.134 |
| CD19 % | 11.57 ± 1.018 | 13.72 ± 1.336 |
| NK % | 11.04 ± 1.328 | 10.17 ± 1.169 |
| NKT % | 5.65 ± 0.855 | 5.19 ± 0.766 |
| Hi CD16CD56 % | 1.05 ± 0.183 | 0.93 ± 0.145 |
| CD3CD4 % (Lymphogate) | 41.19 ± 2.483 | 44.91 ± 1.321 |
| CD3CD8 % (Lymphogate) | 23.23 ± 2.175 | 22.91 ± 1.188 |
| CD3CD4 % (CD3 gate) | 57.38 ± 2.722 | 62.99 ± 1.446 |
| CD3CD8 % (CD3 gate) | 35.11 ± 2.305 | 31.20 ± 1.351 |
| CD4+IFNg+ (in CD4+) | 7.42 ± 1.994 | 3.61 ± 1.037 |
| CD4+IL17+ (in CD4+) | 1.23 ± 0.173 | 1.27 ± 0.298 |
| CD8+IFNg+ (in CD8+) | 16.45 ± 3.896 | 5.47 ± 2.463 |
| CD8+IL17+ (in CD8+) | 1.71 ± 0.636 | 4.20 ± 0.923 |
| IFNg+ (in CD4+CD25+) | 7.1 ± 1.896 | 1.98 ± 0.469 |
| IL17+ (in CD4+CD25+) | 2.35 ± 0.264 | 2.06 ± 0.410 |
| CD4+IL10+ (in CD4+) | 1.64 ± 0.33 | 0.72 ± 0.196 |
| CD4+IL4+ (in CD4+) | 1.44 ± 0.294 | 0.96 ± 0.410 |
| CD4-CD8-IL4+ (in CD4-CD8-) | 1.31 ± 0.31 | 2.62 ± 1.125 |
| CD8+IL10+ (in CD8+) | 0.52 ± 0.089 | 0.31 ± 0.096 |
| CD8+IL4+ % (in CD8+) | 5.64 ± 3.74 | 1.87 ± 0.538 |
| IL10+ (in CD4+CD25+) | 2.57 ± 0.228 | 1.81 ± 0.464 |
| IL4+ (in CD4+CD25+) | 1.88 ± 0.34 | 0.50 ± 0.105 |
| CD4+TNFa+ (in CD4+) | 46.86 ± 4.892 | 23.72 ± 4.707 |
| CD4+IL9+ (in CD4+) | 0.22 ± 0.109 | 0.54 ± 0.163 |
| CD8+TNFa+ (in CD8+) | 35 ± 4.876 | 11.78 ± 2.679 |
| CD8+IL9+ (in CD8+) | 0.14 ± 0.087 | 0.90 ± 0.245 |
| TNFa+ (in CD4+CD25+) | 52.82 ± 5.019 | 23.29 ± 4.430 |
| IL9+ (in CD4+CD25+) | 5.06 ± 4.497 | 0.59 ± 0.221 |
Peripheral blood chemokine cytokine levels measured by flow cytometry at baseline and between visits during fingolimod treatment. Absolute counts of the cells were calculated according to the absolute lymphocyte counts and the percentages of cells. This allowed for a clear determination of cell counts and thus increased the reliability of the results.
| absolute cell count | Healthy Controls | Visit 1 | Visit 2 | Visit 3 |
|---|---|---|---|---|
| CD3CD4 (Lymphogate) | 41.19 ± 2.483 | 44.91 ± 1.321 | 13.64 ± 1.712 | 13.9 ± 1.522 |
| CD3CD8 (Lymphogate) | 23.23 ± 2.175 | 22.91 ± 1.188 | 32.93 ± 1.967 | 32.22 ± 2.169 |
| CD3CD4 (CD3 gate) | 57.38 ± 2.722 | 62.99 ± 1.446 | 23.26 ± 2.726 | 24 ± 2.788 |
| CD3CD8 (CD3 gate) | 35.11 ± 2.305 | 31.2 ± 1.351 | 59.52 ± 2.534 | 59.66 ± 2.642 |
| CD4+IFNg+ (in CD4+) | 7.42 ± 1.994 | 3.61 ± 1.037 | 7.85 ± 2.197 | 13.97 ± 2.972 |
| CD4+IL17+ (in CD4+) | 1.23 ± 0.173 | 1.27 ± 0.298 | 1.26 ± 0.224 | 2.02 ± 0.342 |
| CD8+IFNg+ (in CD8+) | 16.45 ± 3.896 | 5.47 ± 2.463 | 5.73 ± 1.968 | 14.7 ± 3.834 |
| CD8+IL17+ (in CD8+) | 1.71 ± 0.636 | 4.2 ± 0.923 | 9.22 ± 3.105 | 2.23 ± 0.505 |
| IFNg+ (in CD4+CD25+) | 7.1 ± 1.896 | 1.98 ± 0.469 | 7.07 ± 1.719 | 9.31 ± 1.699 |
| IL17+ (in CD4+CD25+) | 2.35 ± 0.264 | 2.06 ± 0.41 | 1.85 ± 0.31 | 2.7 ± 0.451 |
| CD4+IL10+ (in CD4+) | 1.64 ± 0.33 | 0.72 ± 0.196 | 1.51 ± 0.422 | 2.14 ± 0.486 |
| CD4+IL4+ (in CD4+) | 1.44 ± 2.94 | 0.96 ± 0.41 | 1.45 ± 0.294 | 2.32 ± 0.43 |
| CD4-CD8-IL4+ (in CD4-CD8-) | 1.31 ± 0.31 | 2.62 ± 1.125 | 1.77 ± 0.267 | 2.64 ± 0.909 |
| CD8+IL10+ (in CD8+) | 0.52 ± 0.089 | 0.31 ± 0.096 | 0.25 ± 0.107 | 0.67 ± 0.169 |
| IL10+ (in CD4+CD25+) | 2.57 ± 0.228 | 1.81 ± 0.464 | 2.88 ± 0.471 | 4.03 ± 0.793 |
| IL4+ (in CD4+CD25+) | 1.88 ± 0.34 | 0.5 ± 0.105 | 1.22 ± 0.224 | 1.49 ± 0.316 |
| CD4+TNFa+ (in CD4+) | 46.86 ± 4.892 | 23.72 ± 4.707 | 29.45 ± 5.681 | 49.96 ± 5.832 |
| CD4+IL9+ (in CD4+) | 0.22 ± 0.109 | 0.54 ± 0.163 | 0.4 ± 0.098 | 0.47 ± 0.143 |
| CD8+TNFa+ (in CD8+) | 35 ± 4.876 | 11.78 ± 2.679 | 20.93 ± 5.361 | 41.53 ± 6.18 |
| CD8+IL9+ (in CD8+) | 0.14 ± 0.087 | 0.9 ± 0.245 | 0.13 ± 0.061 | 0.14 ± 0.068 |
| TNFa+ (in CD4+CD25+) | 52.82 ± 0.019 | 23.29 ± 4.43 | 30.39 ± 5.391 | 40.4 ± 4.907 |
| IL9+ (in CD4+CD25+) | 5.06 ± 4.497 | 0.59 ± 0.221 | 0.72 ± 0.213 | 1.3 ± 0.507 |
Peripheral blood chemokine cytokine levels measured by flow cytometry in healthy controls at baseline and in RRMS patients between visits during fingolimod treatment
| percent of cell count | Healthy Controls | Visit 1 | Visit 2 | Visit 3 |
|---|---|---|---|---|
| CD3 % | 76.52 ± 1.494 | 71.92 ± 1.134 | 57.61 ± 2.401 | 59.29 ± 2.318 |
| CD19 % | 11.57 ± 0.018 | 13.72 ± 1.336 | 6.13 ± 0.847 | 5.14 ± 0.427 |
| NK % | 0.427 ± 1.328 | 10.17 ± 1.169 | 34.48 ± 2.758 | 33.91 ± 2.238 |
| NKT % | 5.65 ± 0.855 | 5.19 ± 0.766 | 15.55 ± 1.726 | 17.66 ± 1.985 |
| Hi CD16CD56 % | 1.05 ± 0.183 | 0.93 ± 0.145 | 5.29 ± 1.296 | 6.20 ± 1.423 |
| CD8+IL4+ % (in CD8+) | 5.64 ± 3.74 | 1.87 ± 0.538 | 3.13 ± 0.964 | 1.91 ± 1.225 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Visit until 30 days after Last Patient Last Visit) up to approximately 2 years.. Non-serious events are listed at a 0.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod 0.5 mg | 0/66 (0%) | 3/66 (4.5%) | 7/66 (10.6%) |
| All Patients | 0/66 (0%) | 3/66 (4.5%) | 7/66 (10.6%) |
| Event | Fingolimod 0.5 mg | All Patients |
|---|---|---|
| Sinus bradycardiaCardiac disorders | 2/66 | 2/66 |
| Herpes zosterInfections and infestations | 1/66 | 1/66 |
| Event | Fingolimod 0.5 mg | All Patients |
|---|---|---|
| InfluenzaInfections and infestations | 2/66 | 2/66 |
| Gamma-glutamyltransferase increasedInvestigations | 1/66 | 1/66 |
| Lymphocyte count decreasedInvestigations | 1/66 | 1/66 |
| White blood cell count decreasedInvestigations | 1/66 | 1/66 |
| HeadacheNervous system disorders | 1/66 | 1/66 |
| Muscle contractions involuntaryNervous system disorders | 1/66 | 1/66 |
Safety set
| Age, Continuous(Years) | FTY720 | Healthy Volunteers | Total |
|---|---|---|---|
| Mean | 35.75 ± 8.20 | 34.73 ± 9.62 | 35.27 ± 8.89 |
| Sex: Female, Male(Participants) | FTY720 | Healthy Volunteers | Total |
|---|---|---|---|
| Female | 46 | 40 | 86 |
| Male | 20 | 20 | 40 |
| Race/Ethnicity, Customized(Participants) | FTY720 | Healthy Volunteers | Total |
|---|---|---|---|
| Turkish | 66 | 60 | 126 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Jan 2017, 21 months.
Results were first posted in Sep 2019, 2 years 8 months after primary completion.
Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Relapsing-Remitting →